Keyphrases
Zoledronic Acid
100%
Locally Advanced Breast Cancer
100%
Neoadjuvant
100%
Bone Recurrence
75%
Recurrence Rate
62%
Human Epidermal Growth Factor Receptor 2 (HER2)
37%
Breast Cancer Survival
37%
ER +
37%
Overall Survival
25%
Neoadjuvant Chemotherapy
25%
Clinical Endpoints
25%
Bad Times
25%
Clinical Outcomes
12%
No Significant Difference
12%
Breast Cancer
12%
Randomized Placebo-controlled Trial
12%
Newly Diagnosed
12%
Postmenopausal Women
12%
Total Dose
12%
Chemotherapy Alone
12%
Bone-targeting
12%
Bisphosphonates
12%
Neoadjuvant Therapy
12%
First Dose
12%
Follow-up Interval
12%
Active Area
12%
Phase II Clinical Trial
12%
Overall Survival Time
12%
Acid Treatment
12%
Acid Groups
12%
Patients with Breast Cancer
12%
Extraskeletal
12%
Triple Negative
12%
Medicine and Dentistry
Recurrent Disease
100%
Locally Advanced Breast Cancer
100%
Zoledronic Acid
100%
Overall Survival
30%
Breast Cancer Survival
30%
Population Research
20%
Breast Cancer
20%
Neoadjuvant Chemotherapy
20%
Clinical Endpoint
20%
Clinical Trial
10%
Placebo
10%
Clinical Stage
10%
Premenopause
10%
Neoadjuvant Therapy
10%
Bisphosphonate
10%
Survival Time
10%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Recurrent Disease
100%
Zoledronic Acid
100%
Cancer Survival
30%
Overall Survival
30%
Chemotherapy
30%
Population Study
20%
Placebo
10%
Clinical Trial
10%
Bisphosphonic Acid Derivative
10%
Survival Time
10%